These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 21789113)

  • 61. Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature.
    Chan DL; Pavlakis N; Shapiro J; Price TJ; Karapetis CS; Tebbutt NC; Segelov E
    PLoS One; 2015; 10(8):e0135599. PubMed ID: 26275292
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes.
    Pentheroudakis G; Kotoula V; De Roock W; Kouvatseas G; Papakostas P; Makatsoris T; Papamichael D; Xanthakis I; Sgouros J; Televantou D; Kafiri G; Tsamandas AC; Razis E; Galani E; Bafaloukos D; Efstratiou I; Bompolaki I; Pectasides D; Pavlidis N; Tejpar S; Fountzilas G
    BMC Cancer; 2013 Feb; 13():49. PubMed ID: 23374602
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Panitumumab monotherapy compared with cetuximab and irinotecan combination therapy in patients with previously treated KRAS wild-type metastatic colorectal cancer.
    Kennecke H; Chen L; Blanke CD; Cheung WY; Schaff K; Speers C
    Curr Oncol; 2013 Dec; 20(6):326-32. PubMed ID: 24311948
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Systematic review: Anti-epidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancer.
    Dahabreh IJ; Terasawa T; Castaldi PJ; Trikalinos TA
    Ann Intern Med; 2011 Jan; 154(1):37-49. PubMed ID: 21200037
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Targeted agents and oxaliplatin-containing regimens for the treatment of colon cancer.
    Bonetti A; Giuliani J; Muggia F
    Anticancer Res; 2014 Jan; 34(1):423-34. PubMed ID: 24403498
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Current and advancing treatments for metastatic colorectal cancer.
    Sanz-Garcia E; Grasselli J; Argiles G; Elez ME; Tabernero J
    Expert Opin Biol Ther; 2016; 16(1):93-110. PubMed ID: 26549053
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The efficacy and safety of panitumumab administered concomitantly with FOLFIRI or Irinotecan in second-line therapy for metastatic colorectal cancer: the secondary analysis from STEPP (Skin Toxicity Evaluation Protocol With Panitumumab) by KRAS status.
    Mitchell EP; Piperdi B; Lacouture ME; Shearer H; Iannotti N; Pillai MV; Xu F; Yassine M
    Clin Colorectal Cancer; 2011 Dec; 10(4):333-9. PubMed ID: 22000810
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The Predictive Role of Primary Tumour Sidedness in Metastatic Colorectal Cancer Treated With Targeted Agents.
    Fiala O; Ostasov P; Hosek P; Sorejs O; Liska V; Buchler T; Poprach A; Kucera R; Topolcan O; Sustr J; Sedivcova M; Finek J
    Anticancer Res; 2019 Oct; 39(10):5645-5652. PubMed ID: 31570462
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Cetuximab in previously treated colorectal cancer.
    Starling N; Cunningham D
    Clin Colorectal Cancer; 2005 Apr; 5 Suppl 1():S28-33. PubMed ID: 15871763
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials.
    Arnold D; Lueza B; Douillard JY; Peeters M; Lenz HJ; Venook A; Heinemann V; Van Cutsem E; Pignon JP; Tabernero J; Cervantes A; Ciardiello F
    Ann Oncol; 2017 Aug; 28(8):1713-1729. PubMed ID: 28407110
    [TBL] [Abstract][Full Text] [Related]  

  • 71. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer.
    Hecht JR; Mitchell E; Chidiac T; Scroggin C; Hagenstad C; Spigel D; Marshall J; Cohn A; McCollum D; Stella P; Deeter R; Shahin S; Amado RG
    J Clin Oncol; 2009 Feb; 27(5):672-80. PubMed ID: 19114685
    [TBL] [Abstract][Full Text] [Related]  

  • 72. RAS Mutations Beyond KRAS Exon 2: A Review and Discussion of Clinical Trial Data.
    Cannon TL; Kokon MA; Shafqat S; Deeken JF
    Curr Treat Options Oncol; 2015 Jul; 16(7):33. PubMed ID: 26050230
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Genetic Markers of the Host to Predict the Efficacy of Colorectal Cancer Targeted Therapy.
    De Mattia E; Bignucolo A; Toffoli G; Cecchin E
    Curr Med Chem; 2020; 27(25):4249-4273. PubMed ID: 31298142
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Diagnosis and Treatment of Metastatic Colorectal Cancer: A Review.
    Biller LH; Schrag D
    JAMA; 2021 Feb; 325(7):669-685. PubMed ID: 33591350
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Molecular targets for colon cancer. VEGF, EGFR - and what else?].
    Röcken C
    Pathologe; 2008 Nov; 29 Suppl 2():200-3. PubMed ID: 18810446
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer.
    Tol J; Koopman M; Cats A; Rodenburg CJ; Creemers GJ; Schrama JG; Erdkamp FL; Vos AH; van Groeningen CJ; Sinnige HA; Richel DJ; Voest EE; Dijkstra JR; Vink-Börger ME; Antonini NF; Mol L; van Krieken JH; Dalesio O; Punt CJ
    N Engl J Med; 2009 Feb; 360(6):563-72. PubMed ID: 19196673
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Impact of Primary Tumor Location on First-line Bevacizumab or Cetuximab in Metastatic Colorectal Cancer.
    Snyder M; Bottiglieri S; Almhanna K
    Rev Recent Clin Trials; 2018; 13(2):139-149. PubMed ID: 29595113
    [TBL] [Abstract][Full Text] [Related]  

  • 78. First-Line Treatment of Metastatic Colorectal Cancer: Interpreting FIRE-3, PEAK, and CALGB/SWOG 80405.
    Elez E; Argilés G; Tabernero J
    Curr Treat Options Oncol; 2015 Nov; 16(11):52. PubMed ID: 26374340
    [TBL] [Abstract][Full Text] [Related]  

  • 79. A short interval between bevacizumab and anti-epithelial growth factor receptor therapy interferes with efficacy of subsequent anti-EGFR therapy for refractory colorectal cancer.
    Taniguchi H; Komori A; Narita Y; Kadowaki S; Ura T; Andoh M; Yatabe Y; Komori K; Kimura K; Kinoshita T; Muro K
    Jpn J Clin Oncol; 2016 Mar; 46(3):228-33. PubMed ID: 26759349
    [TBL] [Abstract][Full Text] [Related]  

  • 80. A network meta-analysis on the efficacy of sixteen targeted drugs in combination with chemotherapy for treatment of advanced/metastatic colorectal cancer.
    Ba-Sang DZ; Long ZW; Teng H; Zhao XP; Qiu J; Li MS
    Oncotarget; 2016 Dec; 7(51):84468-84479. PubMed ID: 27806321
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.